Preliminary experience with personalized and targeted therapy for pediatric brain tumors

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 27-33

  Wolff, Johannes E ^a   Brown, Robert E ^b   Buryanek, Jamie ^b   Pfister, Stefan ^c   Vats, Tribhawan S ^d   Rytting, Michael E ^d  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ATRT; Brain tumor; Choroid plexus carcinoma; GBM; PNET; Targeted therapy

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CELECOXIB; CURCUMIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR BETA; FULVESTRANT; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; RAPAMYCIN; RESVERATROL; RETINOIC ACID; S PHASE KINASE ASSOCIATED PROTEIN; SORAFENIB; STAT3 PROTEIN; TEMOZOLOMIDE; THALIDOMIDE; THIOTEPA; TOPOTECAN; TRANSCRIPTION FACTOR RELA; TROFOSFAMIDE; VASCULOTROPIN A; VINBLASTINE;

ADOLESCENT; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHOROID PLEXUS TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; EVIDENCE BASED MEDICINE; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEDULLOBLASTOMA; MULTIMODALITY CANCER THERAPY; NEUROECTODERM TUMOR; PERSONALIZED MEDICINE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEOMICS; RHABDOID TUMOR; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BORONIC ACIDS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CURCUMIN; DISEASE-FREE SURVIVAL; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; PYRAZINES; PYRIDINES; SIROLIMUS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84861218315     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23402     Document Type: Article

References (30)

1. Rokes CA, Remke M, Guha-Thakurta N, et al. Sorafenib plus valproic acid for infant spinal glioblastoma. J Pediatr Hematol Oncol 2010; 32: 511-514.
2. Hauch H, Sajedi M, Wolff JE. Treatment arms summarizing analysis of 220 high-grade glioma studies. Anticancer Res 2005; 25: 3585-3590.
3. Wolff JE, Berrak S, Koontz Webb SE, et al. Nitrosourea efficacy in high-grade glioma: A survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol 2008; 88: 57-63.
4. Aydin B, Patil M, Bekele N, et al. Vincristine in high-grade glioma. Anticancer Res 2010; 30: 2303-2310.
5. Xu T, Chen J, Lu Y, et al. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: A systematic review and survival-gain analysis. BMC Cancer 2010; 10: 252.
6. Wolff JE, Sajedi M, Coppes MJ, et al. Radiation therapy and survival in choroid plexus carcinoma. Lancet 1999; 353: 2126.
7. Wrede B, Liu P, Ater J, et al. Second surgery and the prognosis of choroid plexus carcinoma-Results of a meta-analysis of individual cases. Anticancer Res 2005; 25: 4429-4433.
8. Wolff JE, Sajedi M, Brant R, et al. Choroid plexus tumours. Br J Cancer 2002; 87: 1086-1091.
9. Mazloom A, Wolff JE, Paulino AC. The impact of radiotherapy fields in the treatment of patients with choroid plexus carcinoma. Int J Radiat Oncol Biol Phys 2010; 78: 79-84.
10. Brown RE. Morphogenomics and morphoproteomics: A role for anatomic pathology in personalized medicine. Arch Pathol Lab Med 2009; 133: 568-579.
11. Brown RE. Morphoproteomics: Exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005; 2: 337-348.
12. Wrede B, Liu P, Wolff JE. Chemotherapy improves the survival of patients with choroid plexus carcinoma: A meta-analysis of individual cases with choroid plexus tumors. J Neurooncol 2007; 85: 345-351.
13. Wolff JE, Ryttting M, Vats T, et al. Treatment of recurrent diffuse intrinsic pontine glioma, experience of MD Anderson Cancer Center. J Neurooncol 2011 (in press).
14. Zhang M, Segerer F, Ketonen L, et al. Prediction of tumour regrowth of pontine glioma using a two-term model. Anticancer Res 2008; 28: 741-749.
15. Horton TM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group study. Clin Cancer Res 2007; 13: 1516-1522.
16. Masoudi A, Elopre M, Amini E, et al. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 2008; 28: 2437-2442.
17. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 2009; 27: 1007-1013.
18. Accurso F. Curcumin cystic fibrosis. J Pediatr Gastroenterol Nutr 2004; 39: 235.
19. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009; 15: 2087-2094.
20. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-1506.
21. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008; 17: 1411-1417.
22. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002; 106: 2231-2237.
23. Das BB, Shoemaker L, Subramanian S, et al. Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: Case report and literature review. J Heart Lung Transplant 2007; 26: 296-298.
24. Gupte GL, Mahadevan S, Clarke JR, et al. Sirolimus-related pulmonary toxicity mimicking 'asthma like' symptoms. World J Gastroenterol 2007; 13: 5151-5153.
25. Driever PH, Wagner S, Hofstadter F, et al. Valproic acid induces differentiation of a supratentorial primitive neuroectodermal tumor. Pediatr Hematol Oncol 2004; 21: 743-751.
26. Wolff JE, Kramm C, Kortmann RD, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 2008; 90: 309-314.
27. Driever PH, Knupfer MM, Cinatl J, et al. Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr 1999; 211: 323-328.
28. Witt O, Schweigerer L, Driever PH, et al. Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 2004; 43: 181.
29. Peyrl A, Azizi A, Czech T, et al. Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma. Pediatr Blood Cancer 2009; 52: 476-480.
30. Zenali MJ, Zhang PL, Bendel AE, et al. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. Ann Clin Lab Sci 2009; 39: 160-166.